Oncolytics Biotech Inc T.ONC

RE:RE:Breast cancer treatment: perspectives on the oncolytic virus

[Noteable]

Advancements in identifying predictive biomarkers for treatment response remain also urgent. Identifying biomarkers associated with the efficacy of OVs can aid in patient stratification, ensuring targeted therapies for individuals most likely to benefit. 

An exciting frontier remains the synergy between OVs and conventional treatments like chemotherapy, radiotherapy, and immunotherapy. Exploring combination therapies can capitalize on their complementary mechanisms, potentially amplifying therapeutic efficacy and overcoming resistance. 

It is also crucial to find strategies that restore the tumour microenvironment and bolster anti- tumour immune responses. This includes interventions that regulate immune checkpoints, modulate cytokine profiles, or stimulate adaptive immune cells within the tumour milieu.

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1375433/full

[ April 11, 2024 /PRNewswire/ — Oncolytics Biotech® Inc a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company’s planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).]

https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-advances-toward-registration-enabling-trial-for-pelareorep-in-breast-cancer-with-submission-of-type-c-meeting-request-to-fda-2/

https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=35983565


April 2024 -   Oncolytic virus-based combination therapy in breast cancer

Highlights

• •

  - Breast cancer's heterogeneity makes single treatments less effective.

• •

  - Oncolytic viruses can work in synergy with other therapies to boost the immune system's ability to target and destroy breast cancer cells.

• •

  - Combination therapy using oncolytic viruses holds promise for enhancing treatment responses and outcomes in heterogeneous breast tumors.

" Oncolytic virus therapy has emerged as an innovative and promising avenue in the realm of cancer treatment. An oncolytic virus is defined as a virus, either genetically engineered or naturally occurring, with the unique capability to selectively kill cancer cells while sparing normal tissues. This sets oncolytic virus therapy apart from conventional gene therapy, where viruses primarily function as carriers for delivering therapeutic genes. In oncolytic virus therapy, the virus takes on an active role as a therapeutic agent, directly targeting and eliminating cancer cells.   

[ Breast cancer is a complex and heterogeneous disease, and its progression often involves various mechanisms and pathways that can limit the efficacy of monotherapy, like single payload antibody drug conjugates (ADCs) ]

Therefore, combining oncolytic viruses with other therapeutic modalities, such as chemotherapy, immunotherapy, or targeted therapies, may offer a more robust and comprehensive approach to treating breast cancer. 

These combination therapies have the potential to target multiple aspects of the disease, enhance the immune response, and overcome resistance mechanisms, ultimately improving the overall outcomes for patients with breast cancer. 

These combination approaches not only address the heterogeneity of cancer but also overcome resistance mechanisms that might otherwise limit the effectiveness of single treatments. The synergy between different treatment modalities can lead to more potent and sustained tumor eradication while minimizing the risk of relapse. Moreover, combination therapy holds the promise of minimizing treatment-related toxicities and enhancing the quality of life for patients.